Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children’s Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

DALLAS, Feb. 15, 2022 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.